[
  {
    "ts": null,
    "headline": "China pharma firms turn to local reagent suppliers to cut costs and delivery times",
    "summary": "SHANGHAI (Reuters) -Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers said, as they seek to cut costs and delivery times.  Western reagent suppliers including U.S.-based Thermo Fisher Scientific and Germany's Merck have profited in the world's second-largest pharmaceutical market from the compounds used in lab tests for analysis and quality control.  But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are spurring Chinese companies to request products from local rivals like Shanghai Titan Scientific and Nanjing Vazyme Biotech instead, the executives and managers said.",
    "url": "https://finnhub.io/api/news?id=398fd6a41d8f04975c7d4d4abb95d381c7e7683465f12ca2e5efdd7ac748ddf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755126349,
      "headline": "China pharma firms turn to local reagent suppliers to cut costs and delivery times",
      "id": 136344856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SHANGHAI (Reuters) -Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers said, as they seek to cut costs and delivery times.  Western reagent suppliers including U.S.-based Thermo Fisher Scientific and Germany's Merck have profited in the world's second-largest pharmaceutical market from the compounds used in lab tests for analysis and quality control.  But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are spurring Chinese companies to request products from local rivals like Shanghai Titan Scientific and Nanjing Vazyme Biotech instead, the executives and managers said.",
      "url": "https://finnhub.io/api/news?id=398fd6a41d8f04975c7d4d4abb95d381c7e7683465f12ca2e5efdd7ac748ddf4"
    }
  },
  {
    "ts": null,
    "headline": "3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever",
    "summary": "A good stock is an even better buy when it's on sale.",
    "url": "https://finnhub.io/api/news?id=78c53e0ca0cef99f378e59df6e9dab35523e016db2c1c4809a4f273db168d558",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755124020,
      "headline": "3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever",
      "id": 136344857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A good stock is an even better buy when it's on sale.",
      "url": "https://finnhub.io/api/news?id=78c53e0ca0cef99f378e59df6e9dab35523e016db2c1c4809a4f273db168d558"
    }
  },
  {
    "ts": null,
    "headline": "PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?",
    "summary": "Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.",
    "url": "https://finnhub.io/api/news?id=b59a7382ab24ae320a1dd9379168cb43dbb8939d95b9279b31facd1b3f8ca225",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755104100,
      "headline": "PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?",
      "id": 136339640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.",
      "url": "https://finnhub.io/api/news?id=b59a7382ab24ae320a1dd9379168cb43dbb8939d95b9279b31facd1b3f8ca225"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Nike share gains lead Dow's 400-point jump",
    "summary": "UnitedHealth, Nike share gains lead Dow's 400-point jump",
    "url": "https://finnhub.io/api/news?id=94149157b24679495128a8c11f6647185a3688dc530c3a8b986dd3682e56eb73",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755095460,
      "headline": "UnitedHealth, Nike share gains lead Dow's 400-point jump",
      "id": 136352524,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Nike share gains lead Dow's 400-point jump",
      "url": "https://finnhub.io/api/news?id=94149157b24679495128a8c11f6647185a3688dc530c3a8b986dd3682e56eb73"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
    "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
    "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091980,
      "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
      "id": 136328328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
      "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92"
    }
  },
  {
    "ts": null,
    "headline": "Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?",
    "summary": "Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.",
    "url": "https://finnhub.io/api/news?id=39c0d26d75f4c4c0cfdc73fdb5edb4a2c3b5734d2b172198bc861833bff60f4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755089520,
      "headline": "Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?",
      "id": 136339641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.",
      "url": "https://finnhub.io/api/news?id=39c0d26d75f4c4c0cfdc73fdb5edb4a2c3b5734d2b172198bc861833bff60f4f"
    }
  },
  {
    "ts": null,
    "headline": "Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge",
    "summary": "The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico’s biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-",
    "url": "https://finnhub.io/api/news?id=96315d5ac0ffceae734f10e5c0152ee802184bd253a4a558c9cfff20f090cc5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755088860,
      "headline": "Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge",
      "id": 136328329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico’s biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-",
      "url": "https://finnhub.io/api/news?id=96315d5ac0ffceae734f10e5c0152ee802184bd253a4a558c9cfff20f090cc5a"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radio",
    "url": "https://finnhub.io/api/news?id=23b4fc405305d7959fe781d6e1d243e6d0079b1949570a31d5197292592930bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755082800,
      "headline": "Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy",
      "id": 136328330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radio",
      "url": "https://finnhub.io/api/news?id=23b4fc405305d7959fe781d6e1d243e6d0079b1949570a31d5197292592930bb"
    }
  },
  {
    "ts": null,
    "headline": "Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation",
    "summary": "Gain valuable insights into the Livestock Monitoring Market with the Livestock Monitoring Companies Quadrant, an in-depth industry analysis identifying technological advancements, product innovations, and key players like Merck & Co., GEA Group, and DeLaval. Livestock monitoring leverages IoT devices and AI to enhance health surveillance, optimize breeding cycles, and boost productivity in response to rising meat and dairy demands. Despite high upfront costs and connectivity issues hindering ado",
    "url": "https://finnhub.io/api/news?id=a29780925140da99fea812fd010ba1cf2c04e07f90612c0eda6375a393ef899e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755081060,
      "headline": "Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation",
      "id": 136328331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Gain valuable insights into the Livestock Monitoring Market with the Livestock Monitoring Companies Quadrant, an in-depth industry analysis identifying technological advancements, product innovations, and key players like Merck & Co., GEA Group, and DeLaval. Livestock monitoring leverages IoT devices and AI to enhance health surveillance, optimize breeding cycles, and boost productivity in response to rising meat and dairy demands. Despite high upfront costs and connectivity issues hindering ado",
      "url": "https://finnhub.io/api/news?id=a29780925140da99fea812fd010ba1cf2c04e07f90612c0eda6375a393ef899e"
    }
  },
  {
    "ts": null,
    "headline": "MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64.8 billion at the midpoint. Its non-GAAP profit of $2.13 per share was 5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=be9ee1b490e8f1547e9ad55abeef01bf462860625f5af67cf1e7636b632b0ec5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057713,
      "headline": "MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period",
      "id": 136328332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64.8 billion at the midpoint. Its non-GAAP profit of $2.13 per share was 5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=be9ee1b490e8f1547e9ad55abeef01bf462860625f5af67cf1e7636b632b0ec5"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From Merck’s Q2 Earnings Call",
    "summary": "Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the market, as sales declined 1.9% year-over-year. Management attributed the drop primarily to weaker demand for GARDASIL in China, which reduced overall growth by 9 percentage points. CEO Robert Davis cited robust performances in oncology and Animal Health, as well as strong launches of new products like WINREVAIR, which has achieved $1 billion in cumulative sales since approval.",
    "url": "https://finnhub.io/api/news?id=89293498b8cd19a2e924234f259fde25dc792b1b81c53f2b7a4f4622fe8d75bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057228,
      "headline": "5 Must-Read Analyst Questions From Merck’s Q2 Earnings Call",
      "id": 136328333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the market, as sales declined 1.9% year-over-year. Management attributed the drop primarily to weaker demand for GARDASIL in China, which reduced overall growth by 9 percentage points. CEO Robert Davis cited robust performances in oncology and Animal Health, as well as strong launches of new products like WINREVAIR, which has achieved $1 billion in cumulative sales since approval.",
      "url": "https://finnhub.io/api/news?id=89293498b8cd19a2e924234f259fde25dc792b1b81c53f2b7a4f4622fe8d75bb"
    }
  }
]